Research Article

The Effectiveness of the Revised Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine (IPTp-SP) in the Prevention of Malaria among Pregnant Women in Northern Ghana

Yaa Nyarko Agyeman 1, Sam Kofi Newton 2, Raymond Boadu Annor 3, and Ellis Owusu-Dabo 2

1Department of Population and Reproductive Health, School of Public Health, University for Development Studies, Tamale, Ghana
2Department of Global and International Health, School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
3Medical laboratory Department, Savelugu Municipal Hospital, Savelugu, Ghana

Correspondence should be addressed to Yaa Nyarko Agyeman; ynyarko@uds.edu.gh

Received 13 July 2020; Revised 9 October 2020; Accepted 26 October 2020; Published 23 November 2020

1. Background

Malaria in pregnancy still remains a public health problem and from 2010, more than 120 million pregnancies in malaria-endemic regions of the world have been suffering yearly malaria-related infant mortality within the range of 75 000–200 000 [1]. In sub-Saharan Africa, Plasmodium falci-parum is reported to be the main infecting parasite, which is responsible for 99% of all malaria in pregnancy [2]. According to the Ghana Health Service (GHS), malaria is the...
leading cause of morbidity in Ghana. In 2012, malaria accounted for 16.8% of the hospitalizations of pregnant women and 3.4% of maternal mortalities [3]. In areas where the parasite transmission is stable, 25 million pregnant women are at risk of malaria infections annually [4, 5]. Hence, health planners have to implement operative measures that control malaria infections throughout the period of pregnancy in order to reduce the risk of malaria-induced birth outcomes [6].

IPTp-SP is the main intervention to prevent malaria during pregnancy [7]. In the past, a systematic review of clinical trials had advocated for the intake of two doses in the first and second pregnancies to effectively reduce the likelihood of severe anaemia, malaria in pregnancy, low birth weight, and perinatal mortality [8, 9]. Later evidence indicated that the use of two SP doses had limited prophylaxis potency and effectiveness in protecting pregnant women against malaria parasitaemia, placental malaria, maternal anaemia, and low birth weight (LBW) [10–15]. Furthermore, the prophylaxis duration of the two doses of SP was restricted to four to six weeks of gestation; so, pregnant women remained highly vulnerable to malaria infections during most of their 40 weeks of pregnancy [16]. Due to these findings, the Evidence Review Group (ERG) of the WHO has recommended that at least three SP doses be taken under Directly Observed Therapy (DOT) from the second trimester (first Antenatal Care (ANC) visit) until delivery to help improve maternal and neonatal health outcomes [5].

Ghana initiated the new WHO IPTp-SP recommendation in 2014, and pregnant women are expected to take a minimum of three doses of SP and a maximum of five doses, with each dose taken through directly observed therapy (DOT). The first dose is taken at the first ANC enrolment in the second trimester and the remaining doses are scheduled to be taken at four-week intervals during regular monthly antenatal visits until delivery [17]. The revised policy has been scaled up in all the regions of Ghana including the 26 districts of the Northern Region, but its effectiveness in reducing maternal malaria parasitaemia after implementation remains unknown. There are several published studies on the superiority of 3 doses of SP over 2 doses; however, most of these studies that led to this policy change were conducted in East Africa [9, 12, 18–22].

Few years after the change of the IPTp-SP policy, some studies have questioned the fundamentals of the policy upgrade. For instance, Igboeli et al. [23] in 2018 reported that the review of the malaria chemoprophylaxis policy worsens the malaria burden among pregnant women. The authors reported 13% depreciation of the national usage of IPT services after policy change [23]. Moreover, a 2014 study by Asundep et al. reported that taking a single IPTp-SP dose protected pregnant women better than multiple dosing in Kumasi, Ghana [24]. In a study conducted in Navorongo of Northern Ghana, the authors reported that higher SP doses were not able to protect pregnant women against episodes of malaria [25].

Relatedly, the IPTp-SP programme delivers antimalarial agents to all pregnant women [26]. This potentially creates local variations of malaria endemicity in countries like Ghana. Thus, the effectiveness of IPTp-SP against malaria during pregnancy would depend on the local malaria transmission intensity as well as the degree of the established protective immunity [27]. Therefore, the aim of the study was to assess the effectiveness of the revised Intermittent Preventive Treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) in the prevention of malaria in pregnancy in Northern Ghana.

2. Methods and Materials

2.1. Study Design. The study involved a prospective cohort of pregnant women who attended antenatal clinic in four health facilities in the Tamale Metropolis (Tamale Teaching Hospital, West Hospital, Central Hospital, and Seventh Day Adventist Hospital). Pregnant mothers that met the study inclusion criteria and sought antenatal care in any of the study facilities were recruited.

The independent variable was IPTp-SP doses and the primary outcome was maternal peripheral malaria parasitaemia. The register at the facilities served as a sampling frame and respondents were randomly sampled out of the number of pregnant women available during each clinic visit. They were enrolled consecutively as they kept reporting to the facility to receive antenatal care.

2.2. Study Population. The study population was sampled from pregnant women in the Northern region of Ghana who attended antenatal clinic at any of the selected study sites, namely, Tamale Teaching Hospital, Tamale West Hospital, Tamale Central Hospital, and Tamale Seventh-Day Adventist Hospital. All participants were at 16 weeks of gestation and/or had experienced quickening.

2.3. Inclusion Criteria. Pregnant women with at least 16 weeks’ gestation and those who attended and delivered in the antenatal clinic were included in the study.

2.4. Exclusion Criteria. Pregnant women who migrated out of the study area before the end of the study period; women who did not deliver in any of the study facilities; and women who tested positive for HIV/AIDS, syphilis, hepatitis B, and sickle cell were excluded the study.

2.5. Sample Size Estimation. The ANC attendance in 2015 for West hospital, Tamale Teaching hospital, Central, and SDA hospital was 19206, 16293, 22409, and 7000, respectively, totaling 64908. Using an estimated proportion of 85% at 95% confidence level and a precision of 3%, assuming a design effect of 2, the sample size obtained was calculated as 1080. We adjusted for a 10% nonresponse rate and the required sample size was increased to 1188.

The number of pregnant women sampled from each study facility was determined by dividing the respective facility antenatal attendance in 2015 with the total attendance of the year (2015) and multiplying the proportion by the study sample size. A quota of 298, 410, 352, and 128
pregnant women were allocated to Tamale Teaching hospital (TTH), Central, West, and SDA hospital, respectively.

2.6. Ethical Consideration. Ethical clearance was obtained from the Committee on Human Research, Publication and Ethics of Kwame Nkrumah University of Science and Technology/Komfo Anokye Teaching Hospital with reference number CHRE/AP/375/16. Written and verbal consent was obtained from all participants.

2.7. Data Collection Techniques and Tools. A pre-validated questionnaire was developed using extracts from the Multiple Indicator Cluster Survey (MICS) with an Enhanced Malaria Module and Biomarker (2011) [28] on maternal and newborn health, originally designed by UNICEF, and also from the published studies [10, 12, 16, 22, 29, 30]. The study questionnaire was designed to obtain the following variables: sociodemographic information (maternal age, marital status, education, residence, ethnicity, and occupation) and insecticide-treated net (ITN) utilization. The questionnaire also captured the intervention history (SP and ITN usage). The data collection spanned a period of 12 months, from September 2016 to August 2017, to help account for seasonality in malaria. To detect malaria parasitaemia at 36 weeks, blood samples were taken from the participants and processed for microscopic analysis at the Tamale Teaching Hospital Laboratory.

Data extracted from the maternal health record book were cross-checked with the register at the ANC in accordance with the study protocol and the participants were subsequently interviewed directly to corroborate the validity of all obtained information.

2.8. Laboratory Testing of Malaria Parasites. Venous blood sample (3 mL) was collected from each participant into an EDTA tube. A drop of blood was placed on a clean frosted microscope slide and was spread to a diameter of 2 cm to make a thick blood smear. All slides were labeled with the corresponding participant identification number used for the study. The blood smears were allowed to air-dry and fixed with absolute ethanol on the field before transporting to the Tamale Teaching Hospital laboratory for reading. At the laboratory, the smears were flooded with 5% Giemsa solution and allowed to stand for 5 minutes. The slides were washed and air-dried before microscopy [31, 32]. All slides were observed under the oil immersion objective lens and blood smears were classified as negative if no malaria parasites were identified after 1,000 white blood cell (WBC) count and positive if malaria parasites were detected at any stage of the WBC count. The microscopy was done by two different senior medical laboratory scientists. All the study slides have been stored in slide storage boxes for five years.

2.9. Data Analysis. All data entry and management were conducted using the Microsoft Excel version 16 and exported to STATA 14 for analysis. Categorical variables were compared using Chi-square tests to measure the statistical significance of the calculated proportions. Data on SP intake was grouped into no IPTp-SP doses, one or two (<3) IPTp-SP doses, and greater than or equal to three (≥3) IPTp-SP doses. The results obtained from the three study groups were compared and associations were drawn between the doses of IPTp-SP taken and maternal malaria parasitaemia at 36 weeks of gestation. Binary logistic regression was computed to determine the risk associated with the exposure variable (SP ingestion) and the study outcome (maternal parasitaemia at 36 weeks of gestation). P < 0.05 was considered statistically significant.

3. Results

3.1. Sociodemographic Characteristics of Study Participants. A total of 1188 pregnant women were sampled from four antenatal clinics in the Tamale metropolis. However, only 1181 were used in the final analysis because 7 were lost to follow-up. As shown in Table 1, the majority (34.1%) were below 24 years old, married (92.8%), Dagomba by ethnicity (77.1%), practiced Islam (89.2%), and were urban dwellers (66.6%). Furthermore, approximately half (49.5%) of women had no formal education and engaged in petty trading (39.4%) (Table 1).

3.2. Reproductive Health and Obstetric History of Participants. The majority of the study participants had visited the antenatal clinic for the first time during their second trimester of pregnancy (53.9%), were multigravidae (47.6%) and multiparous (45.1%). Approximately 64.7% owned ITNs and 44.3% used them at home. Malaria parasitaemia at registration during the first ANC visit was low (4.5%) among the participants (Table 2).

3.3. Prevalence of Malaria in Pregnancy. As shown in Figure 1, 20.2% of the pregnant women reported no usage of IPTp-SP doses, 37.4% reported usage of 1 or 2 doses of IPTp-SP doses, while 42.4% of the women reported adherence to the WHO-recommended IPTp-SP dose policy (at least 3 doses).

The overall prevalence of malaria was 25.9% in the study population. The malaria prevalence was 35.8% in the no SP group, 30.8% among those who took 1 or 2 SP doses, and 16.9% among those who took three or more doses of SP. There was a significant relationship between the reported SP usage and peripheral malaria parasitaemia at 36 weeks of gestation (X^2 = 14.73, P < 0.001). Malaria prevalence decreased with increased IPTp-SP use. IPTp-SP showed a dose-dependent association with late gestational malaria parasitaemia in pregnancy (36 weeks) (P < 0.001). It could be seen that there was an association between reported ITN/SP use and malaria prevalence (X^2 = 26.75, P < 0.001). Pregnant women who neither use ITN nor IPTp-SP had the highest prevalence (38.8%), compared to those who reported combined use of ITN and IPTp-SP (18.4%), only ITN (30.6%), and only IPTp-SP (27.7%). There was not much difference in the prevalence of malaria among pregnant women who reported usage of either ITN (30.6%) or IPTp-SP (27.7%) (Table 3).
3.4. Association between IPTp-SP Doses and Malaria Prevalence in Pregnancy. As shown in Table 4, there was a significant association between SP use and the prevalence of malaria. Where use of ≥3 doses of IPTp-SP was associated with 56% decrease in the risk of peripheral parasitaemia (aOR 0.44; 95%CI 0.27–0.70; \( P \leq 0.001 \)), compared to those who did not take any IPTp-SP (aOR 0.96; 95%CI 0.63–1.47; \( P \leq 0.86 \)). There was no evidence that 1 or 2 doses of SP provide protection. From the table, it was seen that those who reported combined use of ITN and IPTp-SP were 48% less likely to get malaria (aOR 0.52; 95%CI 0.31–0.89); \( P = 0.02 \), compared to pregnant women who neither used ITN nor IPTp-SP.

4. Discussion

4.1. Prevalence of Malaria in Pregnancy. The implementation of the IPTp-SP policy had been saddled with frequent shortages of SP, which has denied pregnant women on antenatal appointments access to the programme drug (SP) in many parts of the malaria-endemic regions in sub-Saharan Africa [29]. Furthermore, some women tend to be inconsistent with their visits to the antenatal clinic and this has contributed to inequalities of SP supply [30].

The findings of this study showed that 42.4% of the pregnant women adhered to the WHO-recommended ≥3 IPTp-SP doses. This finding was consistent with similar reports in the Western region of Ghana (47.7%) [30], Burkina Faso (49.2%) [33], and Tanzania (40.6–52.6) [34]. However, our measured percentage of reported IPTp-SP uptake (42.4%) was higher than published ranges in Uganda (7.0–8.0%) [35], north-western Tanzania (6.0%) [28], and Gambia (3.8%) [33]. This might be due to differences in implementation challenges, procurement bottlenecks, variations in the intensity of malaria transmission geographically, health worker delays, and irregular subscription of the IPTp-SP services by pregnant women [16, 29, 30, 36, 37].

In a high malaria intensity country like Ghana, increased SP dosing (at least three doses) was required to protect pregnant women against gestational malaria [16, 37]. The prevalence of malaria at 36 weeks of gestation was higher in non-SP users (35.8%), compared to pregnant women who used at least one dose of SP users (23.4%). This is in agreement with a previous study in Takoradi (Ghana) by Orish et al. and other published results elsewhere in Africa [16, 29, 30]. In addition, in Tanzania, non-IPTp-SP users recorded higher malaria prevalence in pregnancy (41.7–43.1%) than women who took two (25.3–36.8%) or at least three (14.7–15.4%) SP doses [16, 29]. Again, the prevalence of malaria at 36 weeks of gestation was significantly decreased from 35.8% in non-SP dose users,
compared to 16.9% in ≥3 SP dose users. The post IPTp-SP malaria prevalence was inconsistent with published percentages in Benin (4–16%) [37], Nigeria (7.7%) [33], and Ghana (7.9–11.2%) [25, 38]. Antenatal clinics play a significant role in combating maternal and infant mortality. This might be the reason why pregnant women saw the need to take at least three doses of SP.

The prevalence of malaria at 36 weeks of gestation was high among pregnant women who neither used ITN nor IPTp-SP (38.8%), compared to those who combined the use of ITN and IPTp-SP (18.4%). Again, the prevalence of malaria was higher in ITN users (30.6%), compared to those who used IPTp-SP (27.7%). The prevalence seen in the current study was higher than the findings of previous studies in Ghana, Nigeria, and Kenya. The prevalence of malaria was 10.5% among ITN users in the Ashanti region of Ghana [39]; 7.2%, 8.6%, and 4.5% among ITN, IPTp-SP, and both IPTp-SP and ITN users, respectively, in Nigeria [40]; and 12.8% among ITN users in Kenya [41]. The difference in the prevalence could be attributed to changes in

![Figure 1: Reported usage of SP among the study respondents.](image)

| Variable | Reported usage of SP | Malaria parasites at 36 weeks, n (%) | $X^2$ | $P$-value |
|----------|----------------------|--------------------------------------|------|-----------|
| Did not take SP | 149 (64.2) | 83 (35.8) | 14.73 | <0.0001 |
| Took SP | 700 (76.6) | 214 (23.4) | | |

| Variable | SP dosage | Malaria parasites at 36 weeks, n (%) | $X^2$ | $P$-value |
|----------|------------|--------------------------------------|------|-----------|
| No SP | 149 (64.2) | 83 (35.8) | 37.86 | <0.0001 |
| <3 dose | 296 (69.2) | 132 (30.8) | | |
| ≥3 dose | 404 (83.1) | 82 (16.9) | | |

| Variable | Reported ITN/SP usage | Malaria parasites at 36 weeks, n (%) | $X^2$ | $P$-value |
|----------|-----------------------|--------------------------------------|------|-----------|
| No ITN/SP use | 90 (61.2) | 57 (38.8) | 26.75 | <0.001 |
| Only SP use | 355 (72.3) | 136 (27.7) | | |
| Only ITN use | 59 (69.4) | 26 (30.6) | | |
| Both SP and ITN use | 345 (81.6) | 78 (18.4) | | |

Data are presented as count (percent). Categorical variables are compared using the Chi-square test, and $P < 0.05$ are considered statistically significant.

| Variable | Univariate regression | Multivariable regression |
|----------|-----------------------|--------------------------|
| Parasitaemia at 36 weeks | | |
| No SP | 1.00 (ref) | 1.00 (ref) |
| <3 doses | 0.86 (0.57–1.12) | 0.20 | 0.96 (0.63–1.47) | 0.86 |
| ≥3 doses | 0.36 (0.25–0.52) | <0.001 | 0.44 (0.27–0.70) | 0.001 |

| Reported ITN/SP usage | | |
| No ITN/SP use | 1.00 (ref) | 1.00 (ref) |
| Only SP | 0.60 (0.41–0.89) | 0.01 | 0.82 (0.50–1.37) | 0.46 |
| Only ITN | 0.70 (0.39–1.23) | 0.21 | 0.96 (0.46–2.00) | 0.92 |
| Both SP and ITN | 0.36 (0.24–0.54) | <0.001 | 0.52 (0.31–0.89) | 0.02 |

$cOR =$ crude odd ratio; $aOR =$ adjusted odd ratio; 95% CI = 95% confidence interval; $P < 0.05$ are considered statistically significant; ref = reference (1.00).
geographical locations, level of adherence, and reduced parasite clearance. The utilization of malaria in pregnancy interventions in sub-Saharan Africa was influenced by the individual, the health provider, the system, and/or community factors. These factors affect the intake of IPTp-SP and women often do not take the full doses required to treat infections and provide adequate prophylaxis [42]. The study results confirmed the existence of differences in the protective effect of ITN and IPTp-SP. However, IPTp-SP may still be protective at the individual and community level, unlike in Malawi, where high ITN coverage like that recorded in this setting (>60.0%) masked the effect of IPTp-SP at the community level [43]. The current study findings suggest that the combined use of ITN and IPTp-SP provided additional protection against the prevalence of late gestational malaria (18.4%). In malaria-endemic Africa, combining the usage of IPTp-SP and ITN provides synergistic protection against malaria in pregnancy [43].

4.2. Association between IPTp-SP, ITN, and Malaria Prevalence at 36 Weeks of Gestation. IPTp-SP utilization showed dose-dependent protection against the odds of peripheral malaria infections at 36 weeks of gestation. Intake of 1 or 2 doses provided no protection ($P = 0.86$) while higher doses of three or more provided $56\%$ less likelihood ($P = 0.001$) of late gestational (36 weeks) peripheral malaria. Arinaitwe and colleagues also found that 2 doses of SP could no longer treat and provide malaria prophylaxis to pregnant women enrolled in the IPTp-SP programme [10]. This also corresponds with earlier studies in Tanzania by Mosha et al., and Mpofogo et al., where high SP dose ($\geq 3$) was associated with $60–80\%$ reduced odds of third trimester malaria parasitaemia [16, 29]. The findings of this study also agree with previous studies in Ghana by Orish et al. [30], and within the West African subregion, where the protective efficacy of SP was greater with three or more doses ($63–72\%$ reduced likelihood), compared to doses below three ($13–36\%$ reduced likelihood) [44]. This reiterates the position of malarial authors that higher SP doses ($\geq 3$) provide better protection from malaria during pregnancy [12, 16, 18, 29, 30, 44, 45].

The findings show that the maximum protection against malaria was seen among pregnant women who took 3 or more doses of IPTp-SP, that is, $56\%$ less likelihood of malaria under at least three SP doses. This suggests that the malaria immunity of the study participants remained optimal after three or more IPTp-SP doses. Furthermore, the protective efficacy of SP in our study under three or more doses shifted closer to the lower bracket of protection. That is, $56\%$ versus $60–80\%$ in Tanzania [16, 29], and $56\%$ versus $63–72\%$ in the West African subregion [44]. This might imply that the prevailing factors, such as high parasite transmission intensity, suboptimal use of high SP doses, and the timing of the SP intake, could abruptly shorten the antimalarial protection of at least three SP doses in the study area. Thus, the antimalarial protective potency of three or more doses of IPTp-SP in the study area might be short-lived. This implies that pregnant women could still be in danger of late malaria infection (around 36 weeks) and maternal anaemia during the period where iron and folate are in high demand prior to delivery [46]. In spite of this feat, other studies have reported the loss of efficacy of SP due to the emergence of SP-resistant parasites [43, 47, 48]. Malaria parasites resistant to SP are now spreading and taking dominance because of changing malaria epidemiology [48]. This calls for the need to consider the use of other interventions [49] such as mefloquine as IPT, which was found to be more potent for the prevention of malaria in pregnancy and other adverse effects in pregnancy in a Cochrane Review [50].

Pregnant women who used IPTp-SP, at least one or more times, were not protected in the multivariable regression, compared to those who took three or more doses of IPTp-SP. Using ITN alone without IPTp-SP did not offer maximum protection against malaria. Pregnant women who combined the use of ITN and IPTp-SP were $48\%$ less likely to get malaria, compared to those who used no intervention. These findings are similar to a study conducted in Cameroon [51]. From the study, it could be seen that combining the use of the two interventions (ITN and IPTp-SP) during pregnancy offers the best protection against malaria in pregnancy. This could be attributed to the effectiveness of the SP drug to clear most parasitaemia in the pregnant women and the additional protection provided by bed nets.

4.3. Limitations. This study detected maternal peripheral malaria parasitaemia with the aid of a microscope. However, peripheral parasite densities can remain below the levels that can be detected using a microscope (submicroscopic infections), while parasites either inhabit or do not inhabit the placenta (placental malaria) [52]. Again, analysis of placental samples gives a better description of Malaria in pregnancy. This method logically outlines malaria infections that occurred throughout pregnancy and can classify them as infections that occurred before the first SP dose, or during dose intervals, or past infections [16]. Thus, the burden of malaria may have been underestimated in this study [39]. Yet, the microscopy method can detect malaria parasites in the peripheral blood of most pregnant women who have placental malaria infections of different parasite intensities [53]. Moreover, microscopists can detect mild (62%) and moderate (33%) parasitaemia in the peripheral blood better, respectively, than methods that use placental samples (35% for mild and 38% for moderate parasitaemia) [52]. In addition, microscopy concentrates a greater volume of blood to maximize parasite detection and remains the best method for malaria diagnosis in resource-deficient settings like the study context [2].

Although we attempted to control for known confounding variables at the design and analysis stages, it is possible that biases of nonverifiable claims might have influenced our results. For instance, we could not verify the claims of reported use or nonuse of SP and ITN among the participants. The prospective nature of our study design (cohort study) allowed for a verifiable measurement of the use of SP, unlike studies that relied on the records of antenatal cards and interview answers [10]. In spite of this, our study was strengthened by the high usage of IPTp-SP, that is,
79.8% of the pregnant women took at least one dose of SP, with 42.4% of them taking three or more SP doses. This showed that the majority of the participants remained in the study and demonstrated positivity of completing their SP doses. Hence, our study was more robust and the findings might be closer to the true representation of the general population than the values observed elsewhere [54]. Furthermore, our study categorized pregnant women into three groups (no SP use, 1 or 2 SP use, and ≥3 SP use) with comparable usage of SP doses of 20.2%, 37.4%, and 42.4%, respectively. This powered the study to compare the outcomes between groups that took no SP, one to two SP doses, and three or more SP doses.

5. Conclusion

Pregnant women in the study area still carried high malaria parasitaemia in their peripheral blood at week 36 of gestation in spite of 42.4% of them complying with the revised dosage of at least three IPTp-SP doses at 36 weeks of gestation. IPTp-SP utilization was associated with dose-dependent protection against the odds of peripheral malaria parasitaemia at 36 weeks of gestation. Thus, some level of protection was achieved among the pregnant women who took at least 3 doses of SP (56%). The results of this study support the position of the WHO revised IPTp-SP policy implemented in Ghana since 2014, which recommends the intake of at least three SP doses. This was shown to be beneficial for decreasing the odds of malaria infection during pregnancy, especially around 36 weeks. Therefore, strategies that maximize the coverage of three or more SP doses should be enhanced in the antenatal system such as taking the IPTp-SP under directly observed therapy (DOT). Furthermore, IPTp-SP use targets could be set for antenatal clinics at the community level; i.e., at least 84% of the pregnant women in the community should complete eight maternity care appointments and take five SP doses annually.

Again, the use of both ITN and IPTp-SP reduced the odds of malaria in pregnancy, compared to using a single intervention. Pregnant women should be educated on the combined usage of ITNs and IPTp-SP during pregnancy to help achieve significant results in the struggle to reduce malaria-related complication in pregnancy.

Data Availability

The datasets used during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

YNA conceived the research idea, designed the study, interpreted the participant data on IPTp-SP dose-dependent efficacy, and drafted the manuscript; RBA analyzed and interpreted the data; EOD supervised the study and proofread the manuscript. SN critically reviewed the manuscript and helped in the revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors are grateful to the pregnant women who willingly consented to be part of this study. Again, their special thanks go to Mr. Bani Bannison, the Biomedical Scientist at the Tamale Teaching Hospital, who assisted them with the laboratory investigations, and to the hardworking research assistants, especially Rita Neindow and Alhassan Bukari. The authors are grateful for the technical assistance of the midwives at all the data collection centers, the laboratory technicians, and the staff of the health facilities involved in the study.

References

[1] R. W. Steketee and C. C. Campbell, ”Impact of national malaria control scale-up programmes in Africa: magnitude and attribution of effects,” Malaria Journal vol. 9, no. 1, p. 299, 2010.
[2] WHO, World Malaria Report 2017, World Health Organization, Geneva, Switzerland, 2017.
[3] C. Akotsen-Mensah, ”Management of insects in Ghana,” Ghana Journal of Science, vol. 11, no. 5, pp. 201–242, 2014.
[4] H. L. Guyatt and R. W. Snow, ”Impact of malaria during pregnancy on low birth weight in sub-Saharan Africa,” Clinical Microbiology Reviews, vol. 17, no. 4, pp. 760–769, 2004.
[5] WHO, ”WHO evidence review group: intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP),” Malaria Policy Advisory Committee Meeting, pp. 1–17, 2012.
[6] K. A. Moore, J. A. Simpson, M. J. L. Scoullar, R. McGready, and F. J. I. Fowkes, ”Quantification of the association between malaria in pregnancy and stillbirth: a systematic review and meta-analysis,” The Lancet Global Health, vol. 5, no. 11, pp. e1101–e1112, 2017.
[7] A. Health, WHO Policy Brief for the Implementation of Intermittent Preventive Treatment of Malaria in Pregnancy April 2013 (Revised January 2014), WHO, Geneva, Switzerland, 2014.
[8] P. Garner and A. M. Gülmezoglu, ”Drugs for preventing malaria in pregnant women,” Cochrane Database Systematic Review, vol. 2014, no. 10, Article ID CD000169, 2006.
[9] D. H. Hamer, V. Mwanakasale, W. B. MacLeod et al., ”Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women,” The Journal of Infectious Diseases, vol. 196, no. 11, pp. 1585–1594, 2007.
[10] E. Arinaitwe, ”Intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy: a cross-sectional study from Tororo, Uganda,” PLoS One, vol. 8, no. 9, 2013.
[11] L. Hommerich, ”Decline of placental malaria in southern Ghana after the implementation of intermittent preventive treatment in pregnancy,” Malaria Journal, vol. 6, pp. 1–8, 2007.
[12] K. Kayentao, P. Garner, A. Maria van Eijk et al., ”Intermittent preventive therapy for malaria during pregnancy using 2 vs. 3 or more doses of sulfadoxine-pyrimethamine and risk of low
birth weight in Africa,” *Jama,* vol. 309, no. 6, pp. 594–604, 2013.

[13] N. U. Igboeli, M. O. Adibe, C. V. Ukwe, and C. N. Agwu, “Comparison of the effectiveness of two-dose versus three-dose sulfadoxine-pyrimethamine in preventing adverse pregnancy outcomes in Nigeria,” *Journal of Vector Borne Diseases,* vol. 55, no. 3, pp. 189–196, 2018.

[14] W. E. Harrington, T. K. Mutabingwa, E. Kabyemela, M. Fried, and P. E. Duffy, “Interruption treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance,” vol. 53, pp. 2–8, 2011.

[15] J. Gutman, D. Mwandama, R. E. Wiegand, D. Ali, D. P. Mathanga, and J. Skarbinski, “Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga District, Malawi,” *Journal of Infectious Diseases,* vol. 208, no. 6, pp. 907–916, 2013.

[16] D. Mosha, J. Chilongola, R. Ndeserua, F. Mvingira, and B. Genton, “Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine for the prevention of malaria during pregnancy in Malawi,” *Journal of Infectious Diseases,* vol. 53, no. 3, pp. 215–223, 2011.

[17] I. Valea, “Intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine during pregnancy in Burkina Faso: effect of adding a third dose to the standard two-dose regimen on low birth weight, anaemia and pregnancy outcomes,” *Malaria Journal,* vol. 12, no. 9, pp. 324 pages, 2010.

[18] M. O. F. Health, “Guidelines for Malaria in Pregnancy.”

[19] M. O. F. Health, “Guidelines for Malaria in Pregnancy.”

[20] W. E. Harrington, T. K. Mutabingwa, E. Kabyemela, M. Fried, and P. E. Duffy, “Interruption treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance,” vol. 53, pp. 2–8, 2011.

[21] J. Gutman, D. Mwandama, R. E. Wiegand, D. Ali, D. P. Mathanga, and J. Skarbinski, “Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga District, Malawi,” *Journal of Infectious Diseases,* vol. 208, no. 6, pp. 907–916, 2013.

[22] D. Mosha, J. Chilongola, R. Ndeserua, F. Mvingira, and B. Genton, “Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine for the prevention of malaria during pregnancy in Malawi,” *Journal of Infectious Diseases,* vol. 53, no. 3, pp. 215–223, 2011.

[23] I. Valea, “Intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine during pregnancy in Burkina Faso: effect of adding a third dose to the standard two-dose regimen on low birth weight, anaemia and pregnancy outcomes,” *Malaria Journal,* vol. 12, no. 9, pp. 324 pages, 2010.

[24] M. Luntamo, P. Ashorn, K. Maleta, Y. B. Cheung, B. Mbewe, and T. Kulmala, “Effect of repeated treatment of pregnant women with sulfadoxine-pyrimethamine and azithromycin on preterm delivery in Malawi: a randomized controlled trial,” *The American Journal of Tropical Medicine and Hygiene,* vol. 83, no. 6, pp. 1212–1220, 2010.

[25] M. Luntamo, “The effect of monthly sulfadoxine-pyrimethamine, alone or with azithromycin, on PCR-diagnosed malaria at delivery: a randomized controlled trial,” *PloS One,* vol. 7, no. 7, 2012.

[26] S. J. Filler, P. Kazembe, M. Thigpen et al., “Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi,” *The Journal of Infectious Diseases,* vol. 194, no. 3, pp. 286–293, 2006.

[27] N. U. Igboeli, M. O. Adibe, C. V. Ukwe, and N. C. Agwu, “Prevalence of low birth weight before and after policy change to IPTp-SP in two selected hospitals in southern Nigeria: eleven-year retrospective analyses,” *Biomed Research International,* vol. 2018, Article ID 4658106, 5 pages, 2018.

[28] N. Asunde, “Effect of malaria and geohelminth infection on birth outcomes in Kumasi, Ghana,” *International Journal of Tropical Disease and Health,* vol. 4, no. 5, pp. 582–594, 2014.

[29] F. Anto, I. H. Agongo, V. Asoala, E. Awini, and A. R. Odulo, “Intermittent preventive treatment of malaria in pregnancy: assessment of the sulfadoxine-pyrimethamine three-dose policy on birth outcomes in rural Northern Ghana,” *Journal of Tropical Medicine,* vol. 2019, Article ID 6712685, 10 pages, 2019.

[30] R. D. Newman, A. Hailemariam, D. Jimma et al., “Burden of malaria during pregnancy in areas of stable and unstable transmission in Ethiopia during a nonepidemic year,” *The Journal of Infectious Diseases,* vol. 187, no. 11, pp. 1765–1772, 2003.

[31] M. Desai, “HHS public access,” *Meghna Gutmia,* vol. 62, no. 3, pp. 323–333, 2017.

[32] Ghana Statistical Service, *Ghana Multiple Indicator Cluster Survey with an Enhanced Malaria Module and Biomarker.*

[33] F. J. Mpogoro, D. Matovelo, A. Dosani, S. Ngallala, M. Mugono, and H. D. Mazigo, “Uptake of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria during pregnancy and pregnancy outcomes: a cross-sectional study in Geta district, North-Western Tanzania,” *Malaria Journal,* vol. 13, p. 455, 2014.

[34] V. N. Orish, O. S. Onyeabor, J. N. Boampong et al., “Prevalence of intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-Sp) use during pregnancy and other associated factors in Sekondi-Takoradi, Ghana,” *African Health Sciences,* vol. 15, no. 4, pp. 1087–1096, 2015.

[35] World Health Organization, *WHO. Basic Malaria Microscopy,* Part 1, World Health Organization, Geneva, Switzerland, 2010.

[36] WHO (World Health Organization), *Basic Malaria Microscopy-Training Manual,* World Health Organization, Geneva, Switzerland, 2010.

[37] S. Scott, “Community-based malaria screening and treatment for pregnant women receiving standard intermittent preventive treatment with sulfadoxine-pyrimethamine: a multicenter (the Gambia, Burkina Faso, and Benin) cluster-randomized controlled trial,” *Clinical Infectious Diseases,* vol. 68, no. 4, pp. 586–596, 2019.

[38] R. Ndeserua, A. Juma, D. Mosha, and J. Chilongola, “Risk factors for placental malaria and associated adverse pregnancy outcomes in Rufiji, Tanzania: a hospital based cross sectional study,” *African Health Sciences,* vol. 15, no. 3, pp. 810–818, 2015.

[39] T. A. Abeiku, “Monitoring changes in malaria epidemiology and effectiveness of interventions in Ethiopia and Uganda: beyond Garki Project baseline survey,” *Malaria Journal,* vol. 14, no. 1, p. 337, 2015.

[40] R. E. Mbu, A. W. A. Takang, H. J. Fouedjio, F. Y. Fouelfack, F. N. Tumasang, and R. Toney, “Clinical malaria among pregnant women on combined insecticide treated nets (ITNs) and intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine in Yaounde, Cameroon,” *BMC Women Health,* vol. 14, no. 1, p. 68, 2014.

[41] N. T. Ndam, “Protective antibodies against placental malaria and poor outcomes during pregnancy,” *Benin,* vol. 21, no. 5, 2015.

[42] D. F. Yeboah, R. Afoakwah, E. K. Nwaefuna, O. Verner, and J. N. Boampong, “Quality of sulfadoxine-pyrimethamine given as antimalarial prophylaxis in pregnant women in selected health facilities in central region of Ghana,” *Journal of Parasitol Research,* vol. 2016, Article ID 9231946, 6 pages, 2016.

[43] A. G. Darko, A. Prince, E. F. Jonathan, and E. R. Kd, “Asymptomatic malaria and its effect on parturients who received intermittent preventive treatment, a cross sectional study of the Bekwai District Ghana,” *GSC Biological and Pharmaceutical Sciences,* vol. 4, no. 2, pp. 7–16, 2018.

[44] C. O. Agomo and W. A. Oyibo, “Factors associated with risk of malaria infection among pregnant women in lagos,
Nigeria,” *Infectious Diseases of Poverty*, vol. 2, no. 1, pp. 1–8, 2013.

[41] H. Atiele, G. Zouh, A. Yaw, I. Mwanzo, A. Githeko, and G. Yan, “Insecticide-treated net (ITN) ownership, usage, and malaria transmission in the highlands of western Kenya,” *Parasites and Vectors*, vol. 4, no. 113, pp. 1–10, 2011.

[42] J. D. Odom, A. O. Westfall, T. O. Apinjoh, J. A. Kimbi, E. A. Achidi, and A. T. N. Tita, “Predictors of the use of interventions to prevent malaria in pregnancy in Cameroon,” *Malaria Journal*, vol. 132, no. 16, pp. 1–10, 2017.

[43] G. Feng, J. A. Simpson, E. Chaluluka, M. E. Molyneux, and S. J. Rogerson, “Decreasing burden of malaria in pregnancy in Malawian women and its relationship to use of intermittent preventive therapy or bed nets,” *PLoS One*, vol. 5, no. 8, 2010.

[44] N. Scott, “Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model,” *Malaria Journal*, vol. 17, no. 1, pp. 1–11, 2018.

[45] K. E. Mace, “Evaluation of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a retrospective birth outcomes study in Mansa, Zambia,” *Malaria Journal*, vol. 14, no. 1, p. 69, 2015.

[46] A. F. Fleming, “Tropical obstetrics and gynaecology. 1. Anaemia in pregnancy in tropical Africa,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 83, no. 4, pp. 441–448, 1989.

[47] H. Tagbor, “A non-inferiority, individually randomized trial of intermittent screening and treatment versus intermittent preventive treatment in the control of malaria in pregnancy,” *PLoS One*, vol. 10, no. 8, 2015.

[48] V. Baraka, “High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania,” *Malaria Journal*, vol. 14, no. 1, pp. 1–9, 2015.

[49] V. Braun, “Lack of effect of intermittent preventive treatment for malaria in pregnancy and intense drug resistance in western Uganda,” *Malaria Journal*, vol. 14, p. 372, 2015.

[50] R. González, C. Pons-Duran, M. Piqueras, J. J. Aponte, F. O. ter Kuile, and C. Menéndez, “Mefloquine for preventing malaria in pregnant women,” *Cochrane Database Systematic Review*, vol. 2018, no. 3, Article ID CD011444, 2018.

[51] E. B. Fokam, L. Ngimuh, J. K. Anchang-Kimbi, and S. Wanji, “Assessment of the usage and effectiveness of intermittent preventive treatment and insecticide-treated nets on the indicators of malaria among pregnant women attending antenatal care in the Buea Health District, Cameroon,” *Malaria Journal*, vol. 15, no. 1, p. 172, 2016.

[52] S. A. Omer, “Placental malaria and its effect on pregnancy outcomes in Sudanese women from Blue Nile State,” *Malaria Journal*, vol. 374, no. 16, 2017.

[53] Z. Idris, *High And Heterogeneous Prevalence of Asymptomatic and Sub-Microscopic Malaria Infections On Islands In Lake Victoria, Kenya*, 2016.

[54] D. A. Isah, A. Y. Isah, Y. Thairu, and E. T. Agida, “Effectiveness of 3 doses of intermittent preventive therapy with sulphadoxine-pyrimethamine in pregnancy,” *Annals of Medical and Health Science Research*, vol. 7, no. 1, pp. 52–57, 2017.